Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCavendish Plc Regulatory News (CAV)

Share Price Information for Cavendish Plc (CAV)

Share Price is delayed by 15 minutes
Get Live Data
9.25    0.00 (0.00%)
Bid:
9.00
Ask:
9.50
Spread: 0.50 (5.556%)
Market Cap: £31.06m
CAV Live PriceLast checked at - London Stock Exchange

Intraday Cavendish Plc Share Chart

Full Year Trading Update

1 Apr 2026 07:00

RNS Number : 9437Y
Cavendish PLC
01 April 2026
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain. 

1 April 2026

Cavendish plc ("Cavendish" and together with its subsidiary undertakings, the "Group")

Full Year Trading Update

Consistently Profitable During FY26

Cavendish, a leading UK investment bank, today issues a trading update for the year ended 31 March 2026 ("FY26").

FY26 Financial performance

FY26 Group revenues are expected to be approximately £56m (FY25: £55.6m). Cavendish has been profitable in both halves of the financial year, demonstrating the broad appeal of our service offering and efficiency of our platform.

Net cash balances were £19.2m at 31 March 2026 (FY25 £21.2m). The Board believes a strong, debt-free balance sheet provides financial resilience for the Group and allows us to continue to build our business for the benefit of all our stakeholders.

In the public markets, FY26 delivered a robust performance against a challenging equity issuance backdrop. Fullyear revenues were modestly ahead of FY25 buoyed by the MHA IPO in the first quarter. This was supported by a strong and increased contribution from equity trading and investment companies, demonstrating disciplined execution in capturing available market opportunities. We added 27 new clients during the year, following an increased focus on and investment in client origination. For the first time since our merger, the movement in clients has been net positive during the second half, supporting a stabilisation in retainers and laying foundations for future deal flow. Average fees remained broadly consistent, demonstrating our pricing discipline despite mixed market conditions.

There has been some reduction in private market revenues in the year. The level of deal volume was broadly in line with the previous year, but the average deal size has been somewhat smaller. Encouragingly, underlying deal economics proved resilient, with the rolling twelvemonth median fee increasing, signalling improved quality and sustainability of the core pipeline. Our new offices in Birmingham and Manchester have started well, performing in line with the business plan in their first full year. They have significantly strengthened our local origination capability, which we believe will be another strategic advantage in our offering.

Overall, FY26 reflects a performance underpinned by diversification across revenue streams and continued cost discipline. While headline revenues were constrained by market conditions, progress in client origination and retention, equity distribution and private market fee quality, positions the Group well for a return to sustainable growth as market confidence improves.

Across our business we act for and advise small and mid-sized companies at all stages of their life cycle. The breadth of our business gives clients more options, so we can deliver solutions that are shaped around what matters most to them.

Outlook

Looking ahead, the Group enters FY27 with a strengthening pipeline and an improving operational platform. The quoted client base is increasing, supporting higher recurring retainers and equity issuance activity. A stronger equity distribution capability is expected to generate greater commission income and our regional offices, now fully staffed, are positioned to capture highervalue deal flow. We continue to invest in talent and have welcomed new colleagues with established reputations from some of our larger competitors.

Certain macroeconomic conditions had been trending more positively, with gradually declining interest rates and increased capital allocation towards European markets. However, sentiment remains heavily influenced by the current conflict in the Middle East, and dragged down by the protracted Russia Ukraine war, political uncertainty in the UK, heightened geopolitical risk and continued debate around returns on AI investment.

The longer these issues and in particular the Middle East conflict persist, the more likely they are to impact negatively on outlook. Against this backdrop, the Group remains focused on disciplined execution and tight cost control, maintaining flexibility and resilience in its operating model.

Strategically, priorities remain centred on improving revenue per head through enhanced origination, continued growth in midmarket private M&A, strengthened equity distribution and firmwide adoption of AIenabled processes to drive efficiency, connectivity and scalability across the business.

 

Contacts

Cavendish (Management) Tel: +44 (0) 20 7220 0500

Julian Morse, Co-Chief Executive Officer investor.relations@cavendish.com

John Farrugia, Co-Chief Executive Officer

Ben Procter, Chief Financial Officer

 

Spark Advisory Partners (Nominated Adviser) Tel: +44 (0) 203 368 3550

Matt Davis

 

Cavendish (Broker) Tel: +44 (0) 20 7220 0500

Matt Lewis

 

Hudson Sandler (PR adviser) Tel: +44 (0) 20 7796 4133

Dan de Belder/Rebekah Chapman

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTWPUMCWUPQGBG
12
Date   Source Headline
10th Apr 20263:18 pmRNSDirectors Dealings
1st Apr 20267:00 amRNSFull Year Trading Update
26th Feb 20263:38 pmRNSHolding(s) in Company
3rd Feb 20262:30 pmRNSDirectors Dealings
18th Dec 20259:08 amRNSDirectors Dealings
15th Dec 20254:15 pmRNSDirector Dealing: Correction
11th Dec 20254:00 pmRNSDirector Dealing
2nd Dec 20257:00 amRNSBlock Admission Return and Total Voting Rights
21st Nov 20254:45 pmRNSHolding(s) in Company
30th Oct 20257:00 amRNS2026 Interim Results
16th Oct 202510:23 amRNSDirector Dealing
1st Oct 20257:00 amRNSHalf Year Trading Update: Profitable First Half
16th Sep 202511:00 amRNSResult of AGM
29th Aug 20257:00 amRNSTotal Voting Rights
18th Jul 202512:07 pmRNSPosting of Annual Report and Notice of AGM
8th Jul 20254:39 pmRNSHolding(s) in Company
3rd Jul 202511:13 amRNS-RInvestor Presentation via Investor Meet Company
26th Jun 20257:00 amRNS2025 Full Year Results
24th Jun 202510:32 amRNSResponse to press speculation
2nd Jun 20257:00 amRNSBlock Admission Return and Total Voting Rights
27th May 20259:02 amRNSHolding(s) in Company
1st May 20254:56 pmRNSTotal Voting Rights
1st May 20254:55 pmRNSDirectors Dealings
9th Apr 20254:02 pmRNSDirector Dealing
4th Apr 20257:00 amRNSFull Year Trading Update
4th Feb 202512:39 pmRNSCompany Name Change
31st Jan 202511:26 amRNSDirectors Dealings
31st Jan 202511:22 amRNSDirector Dealings
12th Dec 20242:56 pmRNSDirectors Dealings
2nd Dec 20247:00 amRNSBlock Admission Return and Total Voting Rights
13th Nov 20243:00 pmRNSDirectors Dealings
11th Nov 20247:00 amRNS2025 Interim Results
21st Oct 20242:37 pmRNSDirectors Dealings
7th Oct 20247:00 amRNSHalf Year Trading Update: Profitable First Half
24th Sep 20249:20 amRNSIntended Purchases of Shares by EBT
16th Sep 202412:42 pmRNSResult of AGM
16th Sep 20249:09 amRNSAGM Trading Statement
6th Sep 20247:00 amRNSRule 19.6(c) Confirmation
15th Aug 20243:00 pmRNSDirectors Dealings
1st Aug 20248:44 amRNSPosting of Annual Report and Notice of AGM
26th Jul 20247:00 amRNSTotal Voting Rights
18th Jul 20244:33 pmRNSDirector Dealings
15th Jul 20247:00 amRNS2024 Full Year Results
12th Jun 20242:41 pmRNSHolding(s) in Company
24th May 20247:00 amRNSDirectorate Change
22nd Apr 202410:00 amRNSDirectors Dealings
8th Apr 20247:01 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSChange of Nominated Adviser
4th Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.